Keryx Biopharmaceuticals, Inc. to Host Conference Call on First Quarter 2015 Financial Results
April 27 2015 - 4:30PM
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical
company focused on bringing innovative therapies to market for
patients with renal disease, today announced that a conference call
will be held on Monday, May 4th, 2015 at 8:00 a.m. ET to discuss
financial results for the first quarter 2015 and provide an update
on the Auryxia™ (ferric citrate) launch.
In order to participate in the conference call, please call
1-(888) 396-2320 (U.S.), 1-(774) 264-7560 (outside the U.S.),
call-in ID: KERYX. The call will also be webcast with slides and
accessible through the Investors section of the company's website
at www.keryx.com. The audio replay will be available at
http://www.keryx.com, for a period of 15 days after the call.
Keryx will announce its financial results for this period in a
press release to be issued prior to the call.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, headquartered in New York, is focused
on bringing innovative therapies to market for patients with renal
disease. The Company launched its first FDA-approved product,
Auryxia, in the United States in December 2014. In January 2014,
ferric citrate was approved for the treatment of patients with all
stages of CKD in Japan, where it is being marketed as Riona® by
Keryx's Japanese partner, Japan Tobacco Inc. and Torii
Pharmaceutical Co. Ltd. For more information about Keryx, please
visit www.keryx.com.
CONTACT: Amy Sullivan, Vice President - Corporate Development
and Public Affairs
Keryx Biopharmaceuticals, Inc.
Tel: 617.466.3447
E-mail: amy.sullivan@keryx.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Apr 2023 to Apr 2024